4.8 Article

The Histone Variant MacroH2A1 Is a BRCA1 Ubiquitin Ligase Substrate

Journal

CELL REPORTS
Volume 19, Issue 9, Pages 1758-1766

Publisher

CELL PRESS
DOI: 10.1016/j.celrep.2017.05.027

Keywords

-

Categories

Funding

  1. CPRIT [RP110784]
  2. National Basic Research Program of China (973 Program) [2012CB910300]
  3. Cytometry and Cell Sorting Core at Baylor College of Medicine
  4. NIH [P30 AI036211, P30 CA125123, S10 RR024574]

Ask authors/readers for more resources

The breast- and ovarian-cancer-specific tumor suppressor BRCA1 and its heterodimeric partner BARD1 contain RING domains that implicate them as E3 ubiquitin ligases. Despite extensive efforts, the bona fide substrates of BRCA1/BARD1 remain elusive. Here, we used recombinant GST fused to four UBA domains to enrich ubiquitinated proteins followed by a Lys-epsilon-Gly-Gly (diGly) antibody to enrich ubiquitinated tryptic peptides. This tandem affinity purification method coupled with mass spectrometry identified 101 putative BRCA1/BARD1 E3 substrates. We identified the histone variant macroH2A1 from the screen and showed that BRCA1/BARD1 ubiquitinates macroH2A1 at lysine 123 in vitro and in vivo. Primary human fibroblasts stably expressing a ubiquitination-deficient macroH2A1 mutant were defective in cellular senescence compared to their wild-type counterpart. Our study demonstrates that BRCA1/BARD1 is a macroH2A1 E3 ligase and implicates a role for macroH2A1 K123 ubiquitination in cellular senescence.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available